Alpha Cognition Inc. (ACOG) Spending and interest coverage
- R&D / revenue · 12 months: Value 27.30%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 34.46%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 27.30% | Research and development expense / revenue. Period ending 2026-06-30. $4.17M ÷ $15.26M × 100 ≈ 27.30% |
| Stock-based compensation / revenue · 12 months | 34.46% | Share-based compensation / revenue. Period ending 2026-06-30. $5.26M ÷ $15.26M × 100 ≈ 34.46% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 4.17M USD | Research and Development Expense |
| Revenue | 15.26M USD | |
| Stock-based compensation | 5.26M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -26.66M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.17M | $15.26M | $5.26M | $-26.66M | (m) | 27.30% | 34.46% | (m) | (m) |
| 2026-03-31 | $2.56M | $10.83M | $5.19M | $-27.35M | (m) | 23.68% | 47.99% | (m) | (m) |
| 2025-12-31 | $1.87M | $10.22M | $4.92M | $-22.66M | (m) | 18.28% | 48.16% | (m) | (m) |
| 2025-09-30 | $2.34M | (m) | $4.04M | $-17.28M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $2.76M | (m) | $3.16M | $-14.45M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $3.41M | (m) | $1.99M | $-11.14M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $3.92M | (m) | $979.80K | $-11.86M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $4.88M | (m) | $2.37M | $-9.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |